New hope for lymphoma patients: drug may boost CAR T-Cell success
NCT ID NCT05464719
First seen Jun 26, 2026 · Last updated Jul 16, 2026 · Updated 3 times
Summary
This phase 2 trial is testing whether the drug loncastuximab tesirine (Lonca) can help patients with large B-cell lymphoma who had only a partial response after CAR T-cell therapy achieve a complete remission. About 30 adults will receive Lonca as a consolidation treatment. The study aims to see if this approach can control the cancer better and will also monitor safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- loncastuximab tesirine (Lonca)
- What this could lead to
- If successful, this could offer a new consolidation option to turn partial remissions into complete remissions for patients with large B-cell lymphoma after CAR T-cell therapy.
- What could go wrong
- This is a small, early-phase trial with only 30 participants, so results may not apply broadly. The drug may cause side effects and may not improve outcomes for all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immune cells plus a checkpoint drug outsmart lymphoma?
- Could muscle loss predict blood cancer outcomes?
- Can an immune booster outsmart brain lymphoma?
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Engineered immune cells take aim at Hard-to-Treat lymphomas